Eikon Therapeutics Inc. Common Stock
EIKN | NASDAQ
$5.31
-$0.04 (-0.75%)
At close: Oct 30, 2026, 4:00 PM ET
$5.20
-$0.11 (-2.07%)
Pre-market:
Nov 2, 2026, 6:37 AM ET
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Cash & Equivalents | 143.01M | 161.55M | 104.9M | 104.87M |
Short-Term Investments | 388.57M | 351.03M | 231.07M | 270.99M |
Long-Term Investments | 7.85M | 91.64M | n/a | n/a |
Other Long-Term Assets | 539K | 556K | 11.95M | 10.69M |
Receivables | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a |
Other Current Assets | 15.4M | 16.92M | 12.94M | 14.64M |
Total Current Assets | 546.98M | 529.5M | 348.92M | 390.5M |
Property-Plant & Equipment | 224.21M | 229.13M | 233.86M | 241.15M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 232.59M | 321.33M | 245.82M | 251.84M |
Total Assets | 779.57M | 850.83M | 594.73M | 642.34M |
Account Payables | 6.56M | 6.01M | 681K | 4.28M |
Deferred Revenue | n/a | n/a | n/a | n/a |
Short-Term Debt | 9.45M | 9.74M | n/a | n/a |
Other Current Liabilities | 23.58M | 18.11M | 35K | 58K |
Total Current Liabilities | 55.3M | 45.06M | 55.01M | 44.39M |
Long-Term Debt | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 15M | 10M | 1.17B | 1.17B |
Total Long-Term Liabilities | 257.77M | 255.09M | 1.42B | 1.4B |
Total Liabilities | 313.07M | 300.16M | 1.47B | 1.45B |
Total Debt | 252.22M | 254.83M | 257.32M | 240.73M |
Book Value | 466.5M | 550.67M | -879.03M | -804.35M |
Book Value Per Share | 8.62 | 10.17 | -16.24 | n/a |
Common Stock | 5K | 5K | n/a | n/a |
Retained Earnings | -1.09B | -1B | -920.51M | -840.85M |
Comprehensive Income | n/a | n/a | n/a | n/a |
Shareholders Equity | 466.5M | 550.67M | -879.03M | -804.35M |
Total Investments | 396.41M | 442.66M | 231.07M | 270.99M |
Add to Watchlist
Select watchlists to add or remove EIKN